Posted by Michael Wonder on 13 May 2019
Intellipharmaceutics announces FDA approval for generic Pristiq
10 May 2019 - Intellipharmaceutics announced today that it has received approval from the U.S. FDA for the Company's abbreviated new drug application for desvenlafaxine extended-release tablets in the 50 and 100 mg strengths.
The approved product is a generic equivalent of the branded product Pristiq. Desvenlafaxine extended release tablets are a serotonin and norepinephrine re-uptake inhibitor indicated for the treatment of major depressive disorder.
